You are here

A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).

Last updated on November 13, 2019

FOR MORE INFORMATION
Study Location
Oncology Hematology West, PC dba Nebraska Cancer Specialists
Omaha, Nebraska, 68130 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL), Castration Resistant Prostate Cancer (CRPC), Diffuse Large B-Cell Lymphoma (DLBCL)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Part 1A:Histologically / cytologically confirmed advanced/unresectable or metastatic SCLC, CRPC,
DLBCL and FL that is refractory to or intolerable of SOC, or for which SOC is unavailable.
Note for FL (Parts 1A and 1B) during the dose finding phase of study, follicular lymphoma
patients must have exhausted all standard of care therapies.


Part 1B
:

Histologically confirmed FL patients that have exhausted all standard of care therapies and
have relapsed or refractory disease.


Part 2
:

-Histologically or cytologically confirmed treatment naïve extensive disease SCLC
patients;

- Histologically confirmed FL patients that have exhausted all standard of care
therapies and have relapsed or refractory disease (Part 2B).

- Histological / cytological diagnosis of castration resistant prostate cancer. Received
either abiraterone and/or enzalutamide treatment (chemotherapy naïve ) and has
evidence of prostate cancer progression (per PWG3):

- SCLC patients entering the study in the expansion cohort with at least one
measurable lesion as defined by Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1.

- FL patients entering the study in the expansion cohort with at least one
measurable lesion as defined by Response Evaluation Criteria in Lymphoma (RECIL)
criteria.

- Females and/or male patients age 18 years.

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.

- Adequate Bone Marrow Function

- Adequate Renal Function

- Adequate Liver Function

- Serum pregnancy test (for females of childbearing potential) negative at
screening, and negative serum or urine pregnancy test at baseline prior to
treatment administration.


Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Known symptomatic brain metastases requiring steroids or CNS involvement in FL.
Previously diagnosed brain metastases are eligible if they have been treated and
recovered from the acute effects of radiation therapy or surgery prior to study entry,
have discontinued corticosteroid treatment for these metastases for at least 4 weeks
and are neurologically stable.

- At least 3 weeks since last major surgery (a lesser period is acceptable if decided to
be in the best interest of the SCLC patient).

- Radiation therapy within 4 weeks prior to study entry. Note, patients who have
received radiotherapy must have recovered from any reversible side effects, such as
nausea and vomiting.

- Last systemic anti cancer chemotherapy or small molecule inhibitor treatment within 4
weeks prior to Cycle 1 Day 1, within 2 weeks if prior monoclonal antibody therapy was
included. Prostate cancer cohorts must be chemotherapy naïve.

- Last anti hormonal therapy within 2 weeks prior to C1D1.

- Prior allogenic stem cell transplant (ASCT).

- Prior irradiation to >25% of the bone marrow (see Appendix for Bone Marrow Reserve in
Adults).

- Active and clinically significant bacterial, fungal, or viral infection, including
hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus
(HIV) or acquired immunodeficiency syndrome (AIDS) related illness.

- Any of the following in the previous 6 months: myocardial infarction, congenital long
QT syndrome, Torsades de pointes, arrhythmias (including sustained ventricular
tachyarrhythmia and ventricular fibrillation), right bundle branch block and left
anterior hemiblock (bifascicular block), unstable angina, coronary/peripheral artery
bypass graft, symptomatic congestive heart failure (New York Heart Association class
III or IV), cerebrovascular accident, transient ischemic attack, or symptomatic
pulmonary embolism; ongoing cardiac dysrhythmias of NCI CTCAE Grade 2, atrial
fibrillation of any grade, or QTcF interval >480 msec at screening.

- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal
medical therapy).

- Participation in other studies involving investigational drug(s) within 28 days or 5
half lives of the investigational drug(s) (whichever is longer, excluding monoclonal
antibodies which require a washout of 2 weeks) prior to study entry.

- Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide
(CRPC) or platinum compound.

- Other acute or chronic medical or psychiatric condition, including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the patient inappropriate for entry into this
study.

- Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
patients who are Pfizer employees, including their family members, directly involved
in the conduct of the study.

- Pregnant female patients; breastfeeding female patients; fertile male patients and
female patients of childbearing potential who are unwilling or unable to use 2 highly
effective methods of contraception as outlined in this protocol for the duration of
the study and for at least 28days after the last dose of investigational product.

- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular
disease or previous gastric resection or lap band surgery. Gastroesophageal reflux
disease under treatment with proton pump inhibitors is allowed.

- Current use or anticipated need for food or drugs that are known strong CYP3A4/5
inhibitors, including their administration within 10 days or 5 half lives of the
CYP3A4/5 inhibitor, whichever is longer prior to first dose of investigational
product.

- Current use or anticipated need for drugs that are known strong CYP3A4/5 inducers,
including their administration within 10 days or 5 half lives of the CYP3A4/5 inducer,
whichever is longer prior to the first dose of investigational product.

Trial Details
Administration
The form in which the study drug will be delivered to the patient's body.
Tablets
Placebo
A placebo often looks like the investigational medication, but it has no active ingredient in it.
A placebo is not used in this trial
Duration
The time commitment for participation in the study.
Follow up: Estimated 4 weeks
Screening: Range 0 days
Treatment: At least 24 weeks
Site Visits
Follow up: At least 1 visits
Screening: Estimated 3 visits
Treatment: At least 9 visits
Prior Approval
The study drug has not been approved yet.
Post-Trial Access to Study Drug
Not planned
NCT03460977
Pfizer
Recruiting
A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Official Title  ICMJE A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)
Brief SummaryA Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).
Detailed Description

This is an open label, multi center, Phase 1 dose escalation study of PF 06821497 administered orally as a single agent BID to patients with SCLC, CRPC, DLBCL and FL (Part 1A). For Part 1B (dose escalation monotherapy), PF 06821497 will be administered as monotherapy in patients with FL. For Part 2A (dose escalation combination therapy), PF 06821497 will be administered in combination with SOC in patients with SCLC and CRPC. For Part 2B (dose expansion), PF 06821497 will be administered in combination with SOC in patients with SCLC and CRPC, and as monotherapy in patients with FL.

Part 1A (escalation monotherapy) will assess PF 06821497 administered as a single agent twice daily in a continuous regimen to patients with advanced tumors (SCLC CRPC, DLBCL and FL). A modified toxicity probability interval (mTPI) dose finding design will be applied in 2 4 patient cohorts. The starting dose of PF 06821497 will be 75 mg BID (DL1). Once the safety and adequate target modulation has been established Parts 1B and 2A of the trial will be initiated. Additional dose levels may be investigated, if adequate target inhibition has not been achieved at DL3.

Part 1B [escalation recommended Phase 2 dose (RP2D) finding - monotherapy] will determine the maximum tolerated dose (MTD) of monotherapy in FL (MTD1).

Part 2A (escalation RP2D finding -combination) will determine the MTD of the combination with SOC in patients with SCLC (cisplatin or carboplatin with etoposide, MTD2, MTD3) and CRPC (MTD4). Part 2B (dose expansion) will assess the efficacy of PF 06821497 at the RP2D identified from the Part 2A, in combination with SOC in patients with SCLC (n=16 to 30 for the 2 combination regimens), and CRPC (n=8 to 20) in addition to as a single agent twice daily in patients with FL (n=8 to 20).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Small Cell Lung Cancer (SCLC)
  • Follicular Lymphoma (FL)
  • Castration Resistant Prostate Cancer (CRPC)
  • Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention  ICMJE Drug: PF-06821497
Oral continuous (Part 1)
Study Arms  ICMJE
  • Experimental: DL 1
    PF-06821497 75 mg BID
    Intervention: Drug: PF-06821497
  • Experimental: DL 2
    PF-06821497 150 mg BID
    Intervention: Drug: PF-06821497
  • Experimental: DL 3
    PF-06821497 250 mg BID
    Intervention: Drug: PF-06821497
  • Experimental: DL 4
    PF-06821497 375 mg BID
    Intervention: Drug: PF-06821497
  • Experimental: DL 5
    PF-06821497 500 mg BID
    Intervention: Drug: PF-06821497
  • Experimental: DL 6
    PF-06821497 625 mg BID
    Intervention: Drug: PF-06821497
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 2, 2018)
172
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 24, 2023
Estimated Primary Completion DateDecember 24, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

Histological or cytological diagnosis of advanced / metastatic solid tumor with the following tumor types in individual study parts:

Part 1A:

-Histologically / cytologically confirmed advanced/unresectable or metastatic SCLC, CRPC, DLBCL and FL that is refractory to or intolerable of standard treatment, or for which no curative treatment is available. Note for FL (Parts 1A and 1B) during the dose finding phase of study, follicular lymphoma patients must have exhausted all standard of care therapies.

Part 1B:

Histologically confirmed FL patients that have exhausted all curative therapies and have relapsed or refractory disease.

Part 2:

  • Histologically or cytologically confirmed treatment naïve extensive disease SCLC patients;
  • Histologically confirmed FL patients that are intolerant of or resistant to standard therapy or for which no curative therapy is available and have relapsed or refractory disease (Part 2B).
  • Histological / cytological diagnosis of castration resistant prostate cancer. Received either abiraterone and/or enzalutamide treatment and has evidence of prostate cancer progression (per PWG3):

    • SCLC patients entering the study in the expansion cohort with at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
    • FL patients entering the study in the expansion cohort with at least one measurable lesion as defined by Response Evaluation Criteria in Lymphoma (RECIL) criteria.
    • Females and/or male patients age 18 years.
    • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
    • Adequate Bone Marrow Function
    • Adequate Renal Function
    • Adequate Liver Function
    • Serum pregnancy test (for females of childbearing potential) negative at screening, and negative serum or urine pregnancy test at baseline prior to treatment administration.

Exclusion Criteria:

  • Known symptomatic brain metastases requiring steroids or CNS involvement in FL. Previously diagnosed brain metastases are eligible if they have been treated and recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable. Physiologic replacement doses of corticosteroids are permissible.
  • At least 3 weeks since last major surgery (a lesser period is acceptable if decided to be in the best interest of the SCLC patient).
  • Treatment with more than 2gm acetaminophen per day within 14 days of study entry and on study if required.
  • Chronic liver diseases.
  • History of alcohol abuse or binge drinking in the last 6 months prior to screening.
  • Radiation therapy within 4 weeks prior to study entry. Note, patients who have received radiotherapy must have recovered from any reversible side effects, such as nausea and vomiting.
  • Systemic anti cancer therapy - approved or investigational - within 4 weeks or 5 half-lives, whichever is shorter, prior to study entry, including antibody based agents. Prostate cancer cohorts 2A and 2B must have not received more than 1 previous regimen of systemic chemotherapy in mCPRC setting. SCLC cohorts must be chemotherapy naive for SCLC however may have received one cycle of chemotherapy after discussion with the sponsor.
  • Last anti hormonal therapy within 2 weeks prior to C1D1.
  • Prior stem cell transplant, autologous or allogenic, within 100 days prior to study enrollment or patients who experienced graft veses host disease or who require systemic immune suppressive therapy.
  • Prior irradiation to >25% of the bone marrow.
  • Active and clinically significant bacterial, fungal, or viral infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
  • Any of the following in the previous 6 months: myocardial infarction, congenital long QT syndrome, Torsades de pointes, arrhythmias (including sustained ventricular tachyarrhythmia and ventricular fibrillation), right bundle branch block and left anterior hemiblock (bifascicular block), unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association class III or IV), cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism; ongoing cardiac dysrhythmias of NCI CTCAE Grade 2, atrial fibrillation of any grade, or QTcF interval >480 msec at screening.
  • Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
  • Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC) or platinum compound.
  • Other acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  • Pregnant female patients; breastfeeding female patients; fertile male patients and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 28days after the last dose of investigational product.
  • Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery. Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed.
  • Current use or anticipated need for food or drugs that are known strong CYP3A4/5 inhibitors, including their administration within 10 days or 5 half lives of the CYP3A4/5 inhibitor, whichever is longer prior to first dose of investigational product.
  • Current use or anticipated need for drugs that are known strong CYP3A4/5 inducers, including their administration within 10 days or 5 half lives of the CYP3A4/5 inducer, whichever is longer prior to the first dose of investigational product.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Italy,   Russian Federation,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03460977
Other Study ID Numbers  ICMJE C2321001
Has Data Monitoring CommitteeNo
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product:Yes
Studies a U.S. FDA-regulated Device Product:No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/da....
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateNovember 2019

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now